(Q44390093)

2 December 2017

Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results (English)

1 reference

2 December 2017

1 reference

0 references

adult oligodendroglioma

1 reference

Ali Chahlavi

1

1 reference

2 December 2017

Andrew Kanner

2

1 reference

2 December 2017

David Peereboom

3

1 reference

2 December 2017

Susan M Staugaitis

4

1 reference

2 December 2017

Paul Elson

5

1 reference

2 December 2017

Gene Barnett

6

1 reference

2 December 2017

1 February 2003

1 reference

Journal of Neuro-Oncology

2 December 2017

1 reference

2 December 2017

61

1 reference

2 December 2017

3

1 reference

2 December 2017

267-273

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1022580610598

2 December 2017

0 references

cites work

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

1 reference

12 December 2020

Correlation of clinical features and telomerase activity in human gliomas

1 reference

12 December 2020

Temozolomide chemotherapy in recurrent oligodendroglioma

1 reference

12 December 2020

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

1 reference

12 December 2020

Oligodendrogliomas: the Mayo Clinic experience

1 reference

12 December 2020

Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

1 reference

12 December 2020

Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

1 reference

12 December 2020

Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas.

1 reference

12 December 2020

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p

1 reference

12 December 2020

Low-grade glioma. To treat or not to treat?

1 reference

12 December 2020

Oligodendroglioma: the Rotterdam-Dijkzigt experience.

1 reference

12 December 2020

Cerebral oligodendroglioma: prognostic factors and life history.

1 reference

12 December 2020

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

12 December 2020

Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis

1 reference

12 December 2020

A clinicopathological study of 323 patients with oligodendrogliomas.

1 reference

12 December 2020

Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors

1 reference

12 December 2020

Does chemotherapy benefit the patient with a central nervous system glioma?

1 reference

12 December 2020

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

12 December 2020

Prognostic factors in oligodendroglioma.

1 reference

12 December 2020

CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Successful chemotherapy for recurrent malignant oligodendroglioma.

1 reference

12 December 2020

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

12 December 2020

The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy

1 reference

12 December 2020

Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.

1 reference

12 December 2020

A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study

1 reference

12 December 2020

Management of oligodendrogliomas.

1 reference

12 December 2020

Aggressive oligodendroglioma: a chemosensitive tumor

1 reference

12 December 2020

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

12 December 2020

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

1 reference

12 December 2020

Clinicopathologic correlations in the oligodendroglioma.

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

1 reference

12 December 2020

Chemotherapy for the treatment of oligodendroglial tumors

1 reference

12 December 2020

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

1 reference

12 December 2020

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma.

1 reference

12 December 2020

Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1022580610598

1 reference

Dimensions Publication ID

2 December 2017

0 references

1 reference